New Chinese JV Confident As It Tackles Inhaled Insulin
This article was originally published in PharmAsia News
Executive Summary
China’s Tonghua Dongbao Pharmaceutical is expanding its diabetes portfolio through a joint venture with Harmony Biopharm for a patented insulin inhaler, aiming to build its presence in the specialized therapeutic area and to expand from an API supplier to a full-range product developer.